Form 4: FMR LLC Reports Pre-Scheduled Sale of Beam Therapeutics Shares

FMR LLC, a significant shareholder and director of Beam Therapeutics Inc., reported the sale of 48,374 common shares at $20.50 per share as part of a Rule 10b5-1 plan.

Summary

• FMR LLC, identified as a 10% owner and director of Beam Therapeutics Inc. (BEAM), reported a transaction involving its beneficial ownership.
• On July 30, 2025, FMR LLC disposed of 48,374 shares of Beam Therapeutics Common Stock.
• The shares were sold at a price of $20.50 per share.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled sale.
• Following this transaction, FMR LLC indirectly beneficially owns 2,073,665 shares of Beam Therapeutics Common Stock.
• Indirect holdings include 1,139,443 shares through F-Prime Capital Partners Healthcare Fund V LP and 473 shares through FMR Capital, Inc.

Sentiment

Score: 5

Explanation: The sale of shares by a significant owner is generally viewed with caution, but the disclosure that the transaction was made pursuant to a Rule 10b5-1 plan suggests it was a pre-scheduled event, mitigating immediate negative sentiment.

Positives

• The transaction was made pursuant to a Rule 10b5-1(c) plan, which suggests the sale was pre-scheduled and not based on new, negative discretionary information.

Negatives

• A significant shareholder and director, FMR LLC, reduced its stake in Beam Therapeutics Inc. by selling 48,374 shares.

Risks

• The sale of shares by a large institutional investor could be perceived by some market participants as a lack of confidence, even if pre-planned.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing, as it is a report of a past transaction.

Management Comments

• Abigail P. Johnson is a Director, the Chairman, and the Chief Executive Officer of FMR LLC, with the Johnson family being predominant owners of FMR LLC's Series B voting common shares.

Industry Context

This filing is a routine insider transaction report specific to Beam Therapeutics Inc. and FMR LLC, and does not provide broader industry trends or context.

Stakeholder Impact

• Shareholders: The sale by a significant institutional investor slightly reduces their overall stake, but the pre-planned nature of the transaction under Rule 10b5-1 mitigates concerns about a change in investment thesis.

Key Dates

Recommendation

The filing reports a pre-scheduled sale by a significant institutional investor (FMR LLC) under a Rule 10b5-1 plan. This type of transaction is typically not indicative of a change in the investor's fundamental view of the company, but rather a pre-arranged liquidity event or portfolio rebalancing. Therefore, it does not provide new information that would warrant a change in investment recommendation based solely on this filing.

Keywords

Beam Therapeutics, BEAM, FMR LLC, Insider Sale, Form 4, Beneficial Ownership, Stock Transaction, 10b5-1 Plan, Biotechnology, Gene Editing